| 摘要: |
| 目的：观察重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎对肺功能及干扰素-γ、白细胞介素-10水水平的影响。方法：选取2017年1月至2018年1月于我院接受治疗的小儿毛细支气管炎患儿120例，按随机数字法分为观察组和对照组各60例。对照组给予常规对症治疗，观察组在对照组的基础上给予重组人干扰素α1b雾化吸入，观察两组治疗前后肺功能、IFN-γ、IL-10水平变化情况、临床症状缓解情况及临床疗效。结果：两组患儿治疗前潮气量（TV）、达峰时间比（tPTEF/tE）、达峰容积比（VPTEF/VE）、峰流速（PTEF）、PTEF%比较差异无统计学意义（P>0.05），治疗后两组TV、tPTEF/tE、VPTEF/VE、PTEF、PTEF%与治疗前比较均升高（P<0.05），且观察组均高于对照组（P<0.05）。两组患儿治疗前IFN-γ、IL-10水平比较差异无统计学意义（P>0.05），治疗后两组IFN-γ、IL-10水平与治疗前比较均明显升高（P<0.05），且观察组均高于对照组，差异有统计学意义（P<0.05）。观察组咳嗽、喘息、肺啰音、三凹征等临床症状消失时间均短于对照组，差异有统计学意义（P<0.05）。观察组治疗总有效率96.67%，高于对照组的86.67%，差异有统计学意义（P<0.05）。结论：重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎具有较好的临床效果，可明显缩短患儿病程，提高疗效，改善肺功能和炎症因子水平。 |
| 关键词: 重组人干扰素α1b 雾化吸入，小儿毛细支气管炎 肺功能 |
| DOI：doi:10.13407/j.cnki.jpp.1672.108X.2021.03.009 |
|
| 基金项目: |
|
| Effects of Aerosol Inhalation of Recombinant Human Interferon α1b on Pulmonary Function and Levels of IFN-γ and IL-10 in Children with Bronchiolitis |
| Che Xiangyu, Hao Caihon, Wang Mingfei, Liu Liye, Guo Chunxia |
| (Handan Maternal and Child Health-Care Hospital of Hebei, Hebei Handan 056001, China) |
| Abstract: |
| Objective: To observe the effects of aerosol inhalation of recombinant human interferon α1b on pulmonary function and levels of IFN-γ and IL-10 in children with bronchiolitis. Methods: A total of 120 children with bronchiolitis admitted into our hospital from Jan. 2017 to Jan. 2018 were extracted to be divided into the observation group and the control group via the random number table, with 60 cases in each group. The control group was given conventional symptomatic treatment, while the observation group received aerosol inhalation ofaerosol inhalation of recombinant human interferon α1b on the basis of the control group. Lung function, levels of IFN-γ and IL-10, remission of clinical symptoms before and after treatment and clinical efficacy of two groups were observed. Results: Before treatment, there were no significant differences in tidal volume (TV), TPTEF/TE, VTPTEF /VE, PTEF and PTEF% between two groups (P>0.05). After treatment, TV, tPTEF/tE, VPTEF/VE, PTEF, and PTEF% increased in two groups compared with those before treatment (P<0.05), and the observation group was higher than the control group (P<0.05). There was no significant difference in the levels of IFN-γ and IL-10 between two groups before treatment (P>0.05). After treatment, the levels of IFN-γ and IL-10 in two groups were significantly higher than those before treatment (P<0.05) ), and the observation group was higher than the control group, the difference was statistically significant (P<0.05). The disappearance time of clinical symptoms such as cough, wheezing, pulmonary rales and three concave signs in the observation group was shorter than that in the control group, with statistically significant difference (P<0.05). The total effective rate in the observation group was 96.67%, higher than 86.67% in the control group, and the difference was statistically significant (P<0.05). Conclusion: The clinical efficacy of aerosol inhalation of recombinant human interferon α1b in the treatment of children with bronchiolitis is significant, which can significantly shorten the course of disease, improve the clinical efficacy, and improve the pulmonary function and the levels of inflammatory factors in children. |
| Key words: recombinant human interferon α1b aerosol inhalation children bronchiolitis pulmonary function |
